DMARDs are medicines that are normally prescribed as soon as rheumatoid arthritis is diagnosed, in order to reduce damage to the joints. Rarely, they can have serious side-effects affecting the blood, liver, or kidneys. DMARDS are usually taken for the rest of your life. Because they are taken for a long time you need to have regular blood tests, to see if the DMARDs are having any side-effects.
What are disease-modifying antirheumatic drugs (DMARDs)?
DMARDs are a group of medicines that are used to ease the symptoms of rheumatoid arthritis (RA) and reduce the damaging effect of the disease on the joints. There are quite a few DMARDs available to treat RA. They include: auranofin (oral gold), azathioprine, ciclosporin, penicillamine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate mofetil (MMF), sodium aurothiomalate, and sulfasalazine. They come in various different brand names.
There is a group of newer medicines called biological therapies which can also be used to treat RA. Like DMARDs they have a disease-modifying effect against RA and are sometimes called cytokine modulators or monoclonal antibodies. Biological therapies include: adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, anakinra, abatacept, rituximab and tocilizumab. Biological therapies are not discussed further in this leaflet. See separate leaflet called 'Biological Medicines for Rheumatoid Arthritis'.
DMARDs are also used to treat other conditions - for example: chronic inflammatory skin or bowel disease. However, the rest of this leaflet is only about DMARDs when they are used to treat RA.
What is rheumatoid arthritis?
Arthritis means inflammation of joints. Rheumatoid arthritis (RA) is a common form of arthritis. The main symptoms are pain and stiffness of affected joints. RA is thought to be an autoimmune disease. The immune system normally makes antibodies (small proteins) to attack bacteria, viruses, and other germs. In people with autoimmune diseases, the immune system makes antibodies against tissues of the body. It is not clear why this happens. In people with RA, antibodies are formed against the synovium (the tissue that surrounds joints). This causes inflammation in and around affected joints. Over time this can damage the joint, the cartilage, and parts of the bone near the joint. The most commonly affected joints are the small joints of the fingers, thumbs, wrists, feet, and ankles.
For more information see separate leaflet called 'Rheumatoid Arthritis'.
How do DMARDs work?
We are still not sure exactly how DMARDs work. But it is thought that they work by blocking the way inflammation develops in the joints, by blocking certain chemicals involved in the inflammation process.
When are DMARDs usually prescribed?
DMARDs are prescribed as soon as possible after RA has been diagnosed, by doctors who specialise in treating RA. Most people with RA have flare-ups followed by better spells. During these flare-ups some damage may be done to the joints. If DMARDs are taken in the early stages of RA they can prevent joint damage and help to slow down the progression of the disease.
Which DMARDs are usually prescribed?
Most people are prescribed two DMARDs. This is because taking two DMARDs works better that taking just one. You will normally be offered a choice of taking methotrexate plus one other DMARD, usually sulfasalazine.
Although methotrexate and sulfasalazine are usually offered first they may not suit everyone. Most people find that methotrexate and sulfasalazine are easier to tolerate and have fewer serious side-effects than the other DMARDs. In general, azathioprine, ciclosporin and leflunomide are used when other DMARDs have been tried and have not worked.
When choosing a DMARD your doctor will talk to you about the differences between them, and look for any reasons why you may not be able to take one over another. Some people are only prescribed one DMARD, and others try several before one or more can be found to suit. Your doctor will advise if it is better for you to take one or two DMARDs.
How well and how quickly do DMARDs work?
It can take several weeks or months for DMARDs to ease the pain and inflammation caused by RA. Therefore, in addition, other medicines are normally advised for a time to help control symptoms until DMARDs start working. These may be steroid medicines, anti-inflammatory medicines and/or other painkillers.
Steroids, anti-inflammatory medicines and painkillers ease the pain and reduce inflammation of RA. Anti-inflammatory medicines and painkillers do not provide the benefits that DMARDS give of preventing joint damage and slowing down the disease progression. Steroids can prevent joint damage if they are given in low doses and taken over a long period of time. However, they are not usually prescribed this way anymore. If a DMARD does not work after six months then your doctor will normally change your treatment.
Methotrexate, sulfasalazine intramuscular gold and penicillamine are all thought to work as well as each other. However, in general, methotrexate and sulfasalazine are better tolerated and have less serious side-effects.
What are the possible side-effects?
It is not possible to list all of the adverse effects of each DMARD in this leaflet. However, as with all medicines, there are a number of side-effects that have been reported with each of the DMARDs, some of which are serious. Serious side-effects are rare, but include damage to the liver and blood-producing cells. For more detail see the information leaflet that came with your medicine.
You must talk to your doctor or pharmacist if you develop:
- A sore throat, unexplained bruising, or mouth ulcers (signs of a problem with your blood).
- Nausea (feeling sick), vomiting, abdominal discomfort, jaundice, or dark urine (signs of a problem with your liver).
Also, DMARDs sometimes react with other medicines that you may take. So, make sure your doctor knows of any other medicines that you are taking, including ones that you have bought rather than been prescribed.
See the leaflet that comes with your particular brand for full list of possible side-effects and cautions.
How often do I have to have blood tests when taking a DMARD?
Because these medicines are usually taken for a long time and they can have serious side-effects, it is usual to have regular tests - usually blood tests - whilst you take them. The tests look for some possible side-effects before they become serious.
Before DMARDs are started
Blood tests are always taken before you start treatment with a DMARD. This is to see if your liver, kidneys and blood are normal. If there are any problems, your doctor will talk to you about this. Blood tests help your doctor decide which DMARD is best for you or if another type of treatment is better for you.
After DMARDs are started
In the first six months of treatment blood tests are taken often. How often you have a blood test depends upon which DMARD you are taking. Your doctor will advise. For example, at first it can be every two to four weeks. After six months, if you have no problems, blood tests may then be taken every three months.
What will happen if my blood tests are not normal?
If there is a problem with your blood test you will usually be asked to stop taking the DMARD. Your GP will need to discuss the results of your blood test with the specialist to see what treatment you may need. In most people, once the medicine is stopped the blood, liver or kidneys return to normal.
What is the usual length of treatment?
If DMARDs work well, it is usual to take one or more DMARDs for the rest of your life. When your RA is well controlled, your doctor may advise you to lower the dose (very slowly). This is in order for you to take the lowest dose and to keep the disease under control.
Can I buy DMARDs?
No. They are only available from your pharmacist, with a doctor's prescription.
Who cannot take DMARDs?
It is not possible to list every type of condition or type of person who cannot take each DMARD in this leaflet. However in general, doctors do not prescribe DMARDs if you:
- Are pregnant or breast-feeding.
- Have severe liver or kidney problems.
- Have a severe blood disorder.
- Serious infection and immunodeficiency syndromes.
How to use the Yellow Card Scheme
If you think you have had a side-effect to one of your medicines you can report this on the Yellow Card Scheme. You can do this online at the following web address: www.mhra.gov.uk/yellowcard.
The Yellow Card Scheme is used to make pharmacists, doctors and nurses aware of any new side-effects that medicines may have caused. If you wish to report a side-effect, you will need to provide basic information about:
- The side-effect.
- The name of the medicine which you think caused it.
- Information about the person who had the side-effect.
- Your contact details as the reporter of the side-effect.
It is helpful if you have your medication - and/or the leaflet that came with it - with you while you fill out the report.
Further help and advice.
Arthritis Research UK
Copeman House, St Mary's Court, St Mary's Gate, Chesterfield, Derbyshire, S41 7TD
Tel: 0300 790 0400 Web: www.arthritisresearchuk.org.
18 Stephenson Way, London, NW1 2HD
Helpline: 0808 800 4050 Web: www.arthritiscare.org.uk.
National Rheumatoid Arthritis Society (NRAS)
Unit B4 Westacott Business Centre, Westacott Way, Littlewick Green, Maidenhead, Berks, SL6 3RT
Helpline: 0800 298 7650 Web: www.nras.org.uk
Further reading & references
- Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy, British Society for Rheumatology and British Health Professionals in Rheumatology (2008)
- Rheumatoid arthritis: the management of rheumatoid arthritis in adults, NICE Clinical Guideline (February 2009)
- Guideline for the management of rheumatoid arthritis (after the first 2 years), British Society for Rheumatology and British Health Professionals in Rheumatology (January 2009)
- Quick reference guideline for monitoring of disease-modifying anti-rheumatic drug (DMARD) therapy, British Society for Rheumatology (November 2009)
- Management of early rheumatoid arthritis, Scottish Intercollegiate Guidelines Network - SIGN (February 2011)
- Rheumatoid arthritis; NICE CKS, June 2009
- DMARDs, Prodigy (Aug 2008)
- British National Formulary; 62nd Edition (Sep 2011) British Medical Association and Royal Pharmaceutical Society of Great Britain, London
|Original Author: Dr Tim Kenny||Current Version: Mrs Jenny Whitehall||Peer Reviewer: Dr Tim Kenny|
|Last Checked: 15/12/2011||Document ID: 12233 Version: 1||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.